Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy

Harbeck, N; Ewer, M S; De Laurentiis, M; Suter, T M; Ewer, S M (2011). Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Annals of oncology, 22(6), pp. 1250-1258. Oxford: Oxford University Press 10.1093/annonc/mdq543

Preview

Text mdq543.pdf - Published Version Available under License Publisher holds Copyright. Download (120kB) | Preview

Adjuvant therapy has improved the survival of women with early breast cancer (BC). Meta-analyses suggest that anthracycline-based regimens reduced the annual BC death rate by 40% in women below the age of 50 and 20% in older women. Novel agents designed to modulate abnormal growth factor signaling in and around the BC cell further increase patients' chances of survival. However, both conventional chemotherapeutic agents as well as some of the novel signaling inhibitors can induce important cardiovascular side-effects, potentially attenuating the progress made in recent years. The mechanism of cancer drug-induced cardiovascular complications varies greatly with some compounds inducing irreversible myocardial cell damage, while others lead to temporary cell dysfunction. The challenge of the future will be to prospectively discriminate between irreversible damage which can lead to progressive cardiovascular disease and reversible cardiovascular dysfunctions without further prognostic implications. Since adjuvant therapy for BC is potentially curative, emphasis must be placed on finding treatments combining maximum efficacy with the minimum of long-term side-effects in order to achieve survival with preserved quality of life.

Interest & Impact

Downloads

174 since deposited on 04 Oct 2013
19 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item